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Abstract: 
Background: Selectively increased radioiodine accumulation in thyroid cells by thyrotropin 
(TSH) allows targeted treatment of thyroid cancer. However, the extent of TSH-stimulated 
radioiodine accumulation in some thyroid tumors is not sufficient to confer therapeutic efficacy. 
Hence, it is of clinical importance to identify novel strategies to selectively further enhance TSH-
stimulated thyroidal radioiodine accumulation. 
Methods: PCCl3 rat thyroid cells, PCCl3 cells overexpressing BRAF
V600E
, or primary cultured 
tumor cells from a thyroid cancer mouse model, under TSH stimulation were treated with 
various reagents for 24 hrs. Cells were then subjected to radioactive iodide uptake, kinetics, 
efflux assays, and protein extraction followed by western blotting against selected antibodies.   
Results: We previously reported that Akt inhibition increased radioiodine accumulation in 
thyroid cells under chronic TSH stimulation. Here, we identified Apigenin, a plant-derived 
flavonoid, as a reagent to further enhance iodide influx rate increased by Akt inhibition in 
thyroid cells under acute TSH stimulation. Akt inhibition is permissive for Apigenin’s action, as 
Apigenin alone had little effect. This action of Apigenin requires p38 MAPK activity, but not 
PKC-δ. The increase in radioiodide accumulation by Apigenin with Akt inhibition was also 
observed in thyroid cells expressing BRAF
V600E
 and in primary cultured thyroid tumor cells from 
TRβPV/PV mice. 
Conclusion: Taken together, Apigenin may serve as a dietary supplement in combination with 
Akt inhibitors to enhance therapeutic efficacy of radioiodine for thyroid cancer.   
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Introduction:  
The Na
+
/I
- 
Symporter (NIS) is a glycoprotein expressed on the basolateral membrane of 
thyroid follicular cells that facilitates active uptake of iodide from circulating blood. The iodide 
is further retained in the thyroid follicle by organification, where it is incorporated into the 
tyrosine amino acid residues of thyroglobulin, the precursor of thyroxine (T4) and 
triiodothyronine (T3) thyroid hormones. Thyroidal radioiodine accumulation serves as the basis 
for targeted ablation of post-thyroidectomy remnants. Since radioiodine accumulation in most 
thyroid tumors can be further enhanced by elevation of serum thyrotropin (TSH) levels, many 
patients with recurrent and metastatic thyroid cancers can benefit from radioiodine therapy upon 
administration of recombinant human TSH or T4 withdrawal (1, 2). However, in a substantial 
number of patients, the extent of TSH-stimulated radioiodine accumulation is not sufficient to 
confer therapeutic efficacy. Thus, it is of clinical importance to identify novel strategies to 
selectively further enhance TSH-stimulated thyroidal radioiodine accumulation. 
 
Pharmacological inhibitors targeting signaling pathways activated in thyroid cancers, such as, 
MEK/ERK (3), Hsp90 (4) and PI3K/Akt (5) have been shown to increase radioactive iodide 
uptake (RAIU) in PCCl3 rat thyroid cells. To date, the effect of MEK and BRAF inhibition (6, 7) 
and 17-AAG (4) on increasing RAI accumulation in cultured thyroid cells have been validated in 
mouse models of thyroid cancer (7, 8) and promising results were recently reported in a clinical 
trial for patients treated with a MEK inhibitor as pretreatment for I-131 therapy (9).  
 
We examined the effects of various inhibitors on RAIU in PCCl3 cells, which have 
undergone TSH withdrawal for 5 days followed by acute TSH stimulation for 24 hrs prior to 
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treatment with inhibitors. In this experimental setting, we show that Akt inhibitor (Akti1/2) had 
the greatest extent of increase in RAIU and Apigenin further increased thyroidal RAIU in 
combination with Akti1/2. The action of Apigenin to further increase Akti1/2-induced RAIU in 
thyroid cells is dependent on p38 MAPK activity. Taken together, Apigenin has the potential to 
serve as a dietary supplement along with Akt inhibitors to increase the efficacy of radioiodine 
therapy for patients with advanced thyroid cancer.  
 
Methods: 
Cell culture, reagents and TRβPV/PV mouse model. PCCl3 rat thyroid cells were maintained in 
6H media with 5% bovine serum as described by Liu et al. (5), unless specified otherwise. 
Experiments were performed under acute TSH stimulation, where cells were withdrawn from 
TSH for 5 days (5H media) and then TSH was added back for 24 hrs prior to treatment with 
various reagents for additional 24 hrs, unless specified otherwise. PCCl3/TetOn-BRAF
V600E
, a 
generous gift from Dr. James Fagin, Memorial Sloan Kettering Cancer Center, New York (10) 
and PCCl3/TetOn-PTC1 cells (4) were genetically modified from PCCl3 cells to allow 
doxycycline-inducible expression of BRAF
V600E
 or PTC1 oncogenes respectively. Experiments 
were performed under acute TSH stimulation with or without 2 µg/ml of doxycycline for 48 hrs, 
followed by treatment with reagents for additional 24 hrs. Primary cultured cells from mouse 
thyroid tumors were isolated using a tumor dissociation kit (Miltenyi Biotec Inc., Bergisch 
Gladbach, Germany), according to the manufacturer’s protocol and were cultured in 6H media. 
Reagents used in this study are listed as follows: Akti1/2 also known as Akt inhibitor VIII, 17-
AAG and SB203580 (EMD Millipore, Billerica, MA), LY294002 (Cayman Chemical Company, 
Ann Arbor, MI), PD98059 (Cell Signaling Technology Inc. Beverly, MA), Apigenin and DMSO 
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(Sigma-Aldrich®, St. Louis, MO), BIRB-796 (Selleck Chemicals, Houston, TX) and Silencer® 
select scrambled and PKC-δ siRNAs (Ambion, Austin, TX). Control vector and shAkt1/2 
plasmids were generous gifts from Dr. Mingzhao Xing at The Johns Hopkins University School 
of Medicine. TRβPV/PV genetically engineered mice were obtained from Dr. Sheue-yann Cheng, 
National Cancer Institute, Bethesda (11). 
 
RT
2
 profiler PCR array and Ingenuity Pathway Analysis (IPA). A Rat Epithelial to 
Mesenchymal transition (EMT) RT
2
 Profiler PCR array that profiles the expression of 84 key 
genes was purchased from SABiosciences, Valencia, CA. Total RNA isolated from PCCl3 cells 
treated with DMSO, Akti1/2, and TGF-β was reversed transcribed to cDNA and real-time PCR 
was performed per manufacturer's instructions. Genes with expression levels of Ct value less 
than 30 in either the experimental or the control group along with their fold changes were 
submitted for IPA analysis to predict upstream transcription factors and their activation status. 
Additional downstream targets of these transcription factors were identified by IPA analysis. 
Among targets identified, we searched for ones that are oppositely modulated by Akti1/2 and 
TGF-β.   
 
Transfections. Plasmid transfections were conducted using FuGENE®6 (Promega, Madison, 
WI) for 24 hrs followed by replacement with fresh media for 24 hrs. Stably transfected cells 
were selected under media containing 800 µg/ml of G418 (Life Technologies, Carlsbad, CA) for 
2 weeks with media replacement every other day. Mixed stable clones were then maintained in 
400 µg/ml of G418. Transfections with siRNAs were facilitated by incubating with 
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Lipofectamine® RNAiMAX (Life Technologies) for 24 hrs followed by replacement with fresh 
media with or without drug treatments for 24 hrs. 
 
RAIU, Kinetics and Efflux Assays. These assays were performed as previously described by 
Vadysirisack et al. (3) with I-125 in NaI (80mCi/mmol). Note that RAIU in all figures, except 
efflux assay, represents NIS-mediated RAIU acquired by subtracting background RAIU value 
from parallel experiments in the presence of 100 µM perchlorate. The magnitude of RAIU in the 
presence of perchlorate varies between 10
2
-10
3
 cpm among different trials. However, the 
background values did not vary much among various experimental groups within the same trial.  
Accordingly, the background measurement for each experimental group within each trial was not 
always replicated.  The background value (or the average of replicates) was subtracted from the 
corresponding experimental group before statistical analysis.  
 
Western blot analysis. Cells were lysed and subjected to gel electrophoresis and Western blot 
analysis as previously described (5). In this study, 4-20% gradient Tris-Glycine or Tris HEPES 
SDS-PAGE gels (NuSep Inc. or Bio-Rad Laboratories, Inc) were used, and the NIS protein was 
detected with the PA716 rNIS polyclonal antibody (provided by Dr. B. Rousset) at a dilution of 
1:1500. Phospho-Akt, p38 MAPK, MAPKAPK2 and PKC-δ were detected using 1:1000 dilution 
of antibodies from Cell Signaling Technology Inc., (Cat. 9271, 9212, 3042) and Santa Cruz 
Biotechnology Inc., Dallas, TX (Cat. sc-213) respectively. Horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse IgG secondary antibodies were used accordingly. Equivalent protein 
loading among samples was monitored by probing for β-actin (Abcam plc, Cambridge, MA; Cat. 
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8226) or GAPDH (Cell signaling technology Inc., Cat. 2118). Densitometry analysis was 
performed using ImageJ software.  
 
Cell surface biotinylation. Cell surface biotinylation was performed as previously described (3). 
Equivalent loading of cell surface proteins was monitored by probing for Na
+
/K
+
 ATPase using 
mouse anti-Na
+
/K
+
 ATPase monoclonal antibody (Santa Cruz Biotechnology Inc., Cat. sc-
21712) and enrichment of cell surface proteins was confirmed by absence of β-actin in the cell 
surface eluate. In this study, phosphatase inhibitors were not added to cell lysis buffer. 
 
Statistical analysis. All experiments had at least two independent trials with three replicates for 
each experimental group within each trial. For RAIU assay, all the data values were log10 
transformed to reduce variance and skewness and then linear mixed effects models were used to 
take account of the correlations among observations from the same trial. From the model, all the 
pre-specified comparisons for each experiment were obtained and adjusted for multiple 
comparisons using sequentially rejective Bonferroni test (12, 13) to control type I error at 0.05. 
SAS 9.2 software was used for analysis (SAS Institute Inc., NC). If no significance was found, 
we just interpreted as no significant difference between the compared conditions instead of using 
the included comparisons to exclude the outcome for another comparison. GraphPad Prism 
version 6.0 was used to perform statistical analyses for efflux assay and to determine Km and 
Vmax values for kinetics assay.   
 
Results 
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Akti1/2 increases TSH-stimulated RAIU to the greatest extent among inhibitors examined in 
PCCl3 cells.  
Small molecule inhibitors, such as Akti1/2 (Akt1/2 inhibitor), LY294002 (PI3K 
inhibitor), 17-AAG (Hsp90 inhibitor), PD98059 (MEK/ERK inhibitor), were examined for their 
effect on RAIU in PCCl3 cells under acute TSH-stimulated conditions. Cells withdrawn of TSH 
for 5 days have little RAIU activity and cells regain RAIU activity after addition of TSH for 24 
hrs. As shown in Figure 1, all inhibitors examined significantly further increased TSH-
stimulated RAIU activity. Among them, Akti1/2 increased TSH-stimulated RAIU to the greatest 
extent. Hence, we focused on Akti1/2 and searched for reagents that can further increase RAIU 
in Akti1/2 treated cells.  
 
Among all inhibitors shown to increase RAIU, none of them can further increase RAIU 
in Akti1/2-treated PCCl3 cells. In FRTL-5 rat thyroid cells, TGF-β decreases RAIU (14, 15) and 
we have confirmed the same in PCCl3 cells (data not shown). TGF-β induces EMT (16-18), yet 
Akt inhibition decreases EMT (19-23). Taken together, Akti1/2 and TGF-β modulate both RAIU 
and EMT in an opposite manner. We thus hypothesized that EMT-associated genes may 
modulate RAIU in thyroid cells. We examined expression levels of 84 EMT-associated genes 
using EMT PCR array in cells treated with DMSO, Akti1/2 or TGF-β. The results were subjected 
to IPA analysis, and involucrin, a transglutaminase substrate protein, was predicted to be 
downregulated by Akti1/2 yet upregulated by TGF-β. Since involucrin expression appears to be 
inversely correlated with RAIU, we speculated that Apigenin, a plant-derived flavonoid known 
to inhibit involucrin expression in keratinocytes, may further increase Akti1/2-induced RAIU.  
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Apigenin further increases RAIU in Akti1/2-treated PCCl3 cells.  
Apigenin (20 µM) alone had little effect on RAIU in PCCl3 cells. However, in 
combination with Akti1/2, Apigenin further increased RAIU in TSH-stimulated PCCl3 cells to a 
greater extent than Akti1/2 alone (Figure 2A). While Akti1/2 at 30 µM further increased RAIU 
compared to 10 µM (Figure 2B), cells had evident morphological changes. Apigenin at 50 µM 
did not significantly increase RAIU to a greater extent than 20 µM in the presence of either 10 
µM or 30 µM Akti1/2. Accordingly, 10 µM Akti1/2 and 20 µM Apigenin were chosen for 
further studies. As shown in Figure 2C, 20 µM Apigenin decreased phospho-Akt level in PCCl3 
cells as reported in many other cell types (24-28) and the combination of Apigenin and Akti1/2 
further decreased phospho-Akt levels. The effect of Apigenin to further increase RAIU in cells 
treated with Akt inhibitor was confirmed in cells treated with 5 µM MK2206 (data not shown). 
MK2206 is another allosteric Akt inhibitor that is currently in clinical trials (29). Taken together, 
Apigenin alone had little effect on RAIU, yet it consistently further enhanced RAIU in PCCl3 
cells in combination with Akt inhibitors. 
 
Akt inhibition via shRNA knockdown or via hormonal modulation allows Apigenin to further 
increase RAIU in PCCl3 cells.  
We further investigated whether Akt inhibition by other means would also allow Apigenin to 
increase RAIU in PCCl3 cells. RAIU was increased by ~1.7 fold in PCCl3 cells stably 
transfected with shAkt1/2 (Figure 3A), in which phospho-Akt level was evidently decreased 
(Figure 3B), compared to cells stably transfected with the control plasmid vector. Note that the 
relative molecular mass (Mr) of NIS protein was increased in cells treated with Apigenin in 
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combination with Akt inhibition. As expected, Apigenin further increased RAIU in PCCl3-
shAkt1/2 cells, yet had little effect on RAIU in PCCl3-vector control cells.   
 
It has been shown that phospho-Akt level is decreased in the absence of insulin in FRTL-5 
rat thyroid cells under low-serum culture media (30). To recapitulate this culture condition, 
PCCl3 cells were deprived of TSH and insulin (4H) with 0.2% serum for 5 days, and then 4H 
culture media was replaced with 4H+TSH or 6H (4H+TSH+insulin) culture media for 24 hrs 
before adding either DMSO vehicle or Apigenin for an additional 24 hrs. As shown in Figure 
3C, Apigenin did not increase RAIU in cells cultured in 4H or 6H condition, yet it did further 
increase RAIU in cells with 4H+TSH culture media. Note that phospho-Akt level in cells with 
4H+TSH was lower than that in cells with 4H or 6H culture media (Figure 3D). Apigenin 
suppressed phospho-Akt levels in all three experimental groups and the extent of suppression is 
more pronounced in 0.2% serum than 5% serum conditions (Figure 3D vs. Figure 2B).  
 
Since TSH is required for NIS expression, protein stability, and function, NIS protein is 
absent in cells under 4H conditions.  Accordingly, Apigenin was not able to induce RAIU in the 
absence of TSH. The inability of Apigenin to increase RAIU under 6H conditions may be 
attributed to other effects of insulin rather than a higher phospho-Akt level prior to Apigenin 
addition. Taken together, Akt inhibition appears to be permissive for Apigenin to further increase 
RAIU, yet Apigenin’s action to further enhance RAIU does not correlate with its effect on 
suppressing phospho-Akt levels.  
 
Apigenin further increases iodide influx rate in Akti1/2-treated PCCl3 cells.  
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Since iodide uptake is mediated by NIS protein localized on the cell surface, we examined if 
Apigenin increases cell surface NIS protein levels in Akti1/2-treated PCCl3 cells. As shown in 
Figure 4A, Apigenin did not increase total or cell surface NIS protein levels in Akti1/2-treated 
cells. The absence of β-actin in cell surface fractions confirms the absence of cytosolic proteins. 
Because RAIU activity represents a steady state equilibrium between iodide influx and iodide 
efflux, we investigated whether Apigenin decreases iodide efflux rate in Akti1/2-treated cells. As 
shown in Figure 4B, Apigenin had little effect on the iodide efflux rate, which is different from 
the mechanism of 17-AAG (4).   
 
Effects of Apigenin on maximum velocity of iodide influx (Vmax) and iodide affinity 
(∝1/Km) were evaluated. Similar to previous studies conducted on cells under chronic TSH 
stimulation (5), Akti1/2 alone increases Vmax by 1.44-fold compared to DMSO treated cells. In 
combination with Akti1/2, Apigenin further increased Vmax by 1.24-fold, compared to Akti1/2 
treatment alone with little change in the Km value. Since Apigenin did not increase cell surface 
NIS protein levels, the increase in Vmax suggests that Apigenin increases the rate of iodide 
uptake by each NIS molecule on the cell surface.  
 
Apigenin’s effect to further increase RAIU in Akti1/2-treated cells requires p38 MAPK 
activity.  
Since p38 MAPK is a well-known downstream effector of Apigenin (31-33), we examined if 
p38 MAPK mediates Apigenin’s effect on RAIU in Akti1/2-treated PCCl3 cells. Pretreatment 
with an ATP-pocket binding inhibitor of p38MAPK, SB203580, for 1 hr and its continuous 
presence for 24 hrs diminished Apigenin’s effect to further increase RAIU in Akti1/2-treated 
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cells. The fact that SB203580 treatment decreased RAIU in cells of all experimental groups 
indicates that p38MAPK activity plays a functional role to maintain optimal RAIU activity in 
PCCl3 cells. Apigenin’s effect to further increase RAIU in Akti1/2-treated cells appears to be 
dependent, at least in part, upon p38 MAPK activity (Figure 5A). 
 
SB203580 does not decrease the phosphorylation levels of p38 MAPK but inhibits its 
catalytic activity to phosphorylate its downstream substrates, such as MAPKAPK2. Using 
antibodies against MAPKAPK2, the non-phosphorylated form (lower band) can be resolved 
from the phosphorylated from (upper band). As shown in Figure 5B, MAPKAPK2 was 
predominantly in the phosphorylated form in acute TSH-stimulated PCCl3 cells, and the relative 
abundance of the non-phosphorylated form was increased by SB203580 treatment. The decrease 
of RAIU in SB203580-treated cells was not accompanied with a decrease in total NIS protein 
levels. Note that the relative molecular mass (Mr) of NIS protein was increased in cells treated 
with Apigenin in combination with Akt inhibition. Similar results were obtained using an 
allosteric p38 MAPK inhibitor, BIRB-796 (Figure 5C and Figure 5D). Using siRNA to 
knockdown either each individual or all four isoforms, p38MAPK was knocked down up to 60% 
and this was not sufficient to decrease p38 MAPK activity. Accordingly, neither increase in non-
phosphorylated form of MAPKAPK2, nor decrease in RAIU, was observed (data not shown). 
 
Apigenin’s action to increase RAIU in Akti1/2-treated cells is independent of PKC-δ.  
Another well-known downstream effector of Apigenin is PKC-δ (32, 33). To test if 
Apigenin modulates RAIU via PKC-δ, genetic knockdown of PKC-δ was performed using 
siRNAs. As shown in Figure 6A, neither RAIU in cells of all experimental groups, nor the 
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further increase of RAIU by Apigenin in Akti1/2-treated cells, was affected by PKC-δ 
knockdown. Western blot analysis confirmed that PKC-δ protein levels were considerably 
decreased by siRNA knockdown (Figure 6B). The total NIS protein level was modestly 
decreased by PKC-δ knockdown in acute TSH-stimulated PCCl3 cells, yet without accompanied 
decrease in RAIU activity.  
 
Apigenin in combination with Akti1/2 further increases TSH-stimulated RAIU in BRAF
V600E
 
expressing thyroid cells and thyroid tumor cells from TRβPV/PV mice.  
The BRAF
V600E
 oncogene is the most commonly found oncogene in papillary thyroid 
carcinomas that is associated with aggressive clinical features (34) and reduced radioiodine 
uptake (35). To ensure clinical relevance of this finding, we investigated whether Apigenin’s 
effect on RAIU is reproducible in PCCl3 cells overexpressing the BRAF
V600E
 oncogene and in 
primary cultured cells derived from thyroid tumors of a preclinical mouse model.  
 
As expected, BRAF
V600E
 induction via doxycycline resulted in decreased RAIU (Figure 7A) 
and decreased NIS protein levels (Figure 7B) in PCCl3/Tet-On BRAF
V600E
 cells. Akti1/2 alone 
increased RAIU in both un-induced and doxycycline-induced cells to much lesser extent (Figure 
7A), compared to PCCl3 parental cells. Apigenin alone had little effect on RAIU; however, 
Apigenin was able to further increase RAIU in Akti1/2-treated cells (Figure 7A). Similar results 
were obtained in doxycycline-induced PCCl3/TetOn-PTC1 cells (data not shown). These results 
indicate that increased RAIU by combination treatment of Apigenin and Akti1/2 is not limited to 
non-transformed PCCl3 cells but also present in PCCl3 cells expressing oncogenes that are 
relevant to thyroid cancer patients.  
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TRβPV/PV genetic-engineered mice develop thyroid tumors (36) that maintain NIS expression 
(37). It is of interest to note that combination treatment of Apigenin with Akti1/2 significantly 
increased RAIU in primary cultured cells derived from thyroid tumors developed in TRβPV/PV 
mice (Figure 7C). Taken together, Apigenin in combination with Akti1/2 increases RAIU in 
established rat thyroid cell lines as well as primary cultured cells of thyroid tumors from a 
preclinical thyroid cancer mouse model. 
 
Discussion 
In PCCl3 rat thyroid cells, we show that acute TSH-stimulated RAIU is enhanced by various 
inhibitors targeting signaling nodes over-activated in thyroid tumors. Among them, Akti1/2 
increased RAIU to the greatest extent, and Apigenin further increased RAIU in Akti1/2-treated 
thyroid cells. This action of Apigenin was not mediated by an increase in cell surface NIS 
protein levels or a decrease in iodide efflux rate.  Instead, Apigenin increased iodide influx rate 
in Akti1/2-treated cells, and this effect required p38MAPK activity. Most importantly, the 
increase in TSH-stimulated RAIU activity by Apigenin in combination with Akti1/2 was 
confirmed in BRAF
V600E
 expressing PCCl3 cells as well as in primary cultured tumor cells from 
TRβPV/PV genetic-engineered mice.  
 
Akti1/2 alone increased iodide influx rate, and Apigenin in combination with Akti1/2 further 
increased iodide influx rate (Figure 4C). To this date, molecular mechanisms underlying the 
modulation of iodide influx rate mediated by NIS remain unknown. Phosphorylation has been 
shown to modulate the activity of many transporters, such as glucose transporter (38) and Na
+
/H
+
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Exchanger isoform-1 (39). NIS is a phosphorylated protein (40) and several phosphorylation 
sites have been identified (41). An increase of Mr in NIS protein was noted in cells treated with 
Apigenin in combination with either Akt inhibitor or Akt knockdown in parental and BRAF
V600E
 
expressing PCCl3 cells. In these experimental settings, the increase of Mr in NIS was 
accompanied with an increase in RAIU. It will be of interest to determine whether the increase of 
Mr reflects NIS phosphorylation and whether NIS phosphorylation leads to increased iodide 
influx rate in thyroid cells.  
 
However, an increase of Mr in NIS did not always translate into increased RAIU. As shown 
in Figure 5, one hour pre-treatment of p38 MAPK inhibitor followed by its continuous presence 
for 24 hrs diminished Apigenin’s effect to further increase RAIU in Akti1/2-treated cells despite 
that the increase of Mr in NIS remains unchanged. Conversely, iodide influx rate can be 
upregulated without an increase of Mr in NIS, as in the case of cells treated with Akti1/2 alone. 
Taken together, NIS-mediated iodide influx rate may be modulated by multiple mechanisms. 
 
Akt inhibition alone, via inhibitor or shRNA knockdown, further increased TSH-stimulated 
RAIU in PCCl3 cells. Apigenin alone also decreased phospho-Akt levels, yet with little effect on 
thyroidal RAIU activity. This discrepancy may be explained by a lesser decrease in phospho-Akt 
levels by Apigenin than Akti1/2 or shAkt1/2. Accordingly, one may speculate that a threshold of 
Akt inhibition needs to be achieved to increase RAIU, and that a further increase in RAIU by 
Apigenin in Akti1/2-treated cells was mediated by further Akt inhibition. However, Akt 
inhibition is not always accompanied with increased RAIU. For example, the evident decrease in 
phospho-Akt levels by Apigenin treatment was not accompanied with increased RAIU in PCCl3 
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cells with 0.2% serum culture media. Furthermore, SB203580 diminished Apigenin’s effect to 
further increase RAIU in Akti1/2 treated cells without evident change in phospho-Akt levels. 
Finally, it is of interest to note that an increase of Mr in NIS only occurred in cells treated with 
Apigenin+Akt inhibition. This suggests that Apigenin’s action to further increase RAIU in 
Akti1/2 treated cells may not be fully explained by its effect on further Akt inhibition.  
 
SB203580 decreased TSH-induced NIS mRNA levels, when SB203580 and TSH were added 
at the same time to TSH-deprived FRTL-5 cells (42, 43). In this study, a p38 MAPK inhibitor 
was added 24 hrs after acute TSH stimulation, when NIS mRNA and protein were already 
synthesized. Neither SB203580 nor BIRB-796 altered steady state NIS protein levels, yet both 
resulted in drastic decrease in RAIU. Accordingly, p38 MAPK activity is not only required for 
TSH-stimulated NIS expression but also required for optimal NIS-mediated RAIU activity. 
However, the action of Akti1/2 on RAIU is independent of p38 MAPK activity, as neither 
SB203580 nor BIRB-796 affected the fold of increase in RAIU by Akti1/2 alone.  
 
Matowe et al. reported that PKC-δ disappeared within 24 hrs of TSH withdrawal and 
reappeared 24 hrs after TSH addition in FRTL-5 rat thyroid cells (44). Our study shows that 
steady state NIS protein levels were modestly decreased upon PKC-δ knockdown, yet without 
accompanied change in RAIU. This discrepancy may be explained by an absent change in cell 
surface NIS protein levels or by an increased NIS activity that compensates the decreased NIS 
protein levels. Neither Akti1/2-induced RAIU nor Apigenin’s ability to further increase Akti1/2-
induced RAIU was dependent upon PKC-δ. 
 
 Page 16 of 39
Th
yr
oi
d
A
pi
ge
ni
n 
in
 C
om
bi
na
tio
n 
w
ith
 A
kt
 In
hi
bi
tio
n 
Si
gn
ifi
ca
nt
ly
 E
nh
an
ce
s T
hy
ro
tro
pi
n-
sti
m
ul
at
ed
 R
ad
io
io
di
de
 A
cc
um
ul
at
io
n 
in
 T
hy
ro
id
 C
el
ls 
(do
i: 1
0.1
08
9/t
hy
.20
13
.06
14
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
17 
17 
 
The increase in RAIU by Apigenin+Akti1/2 was reproduced in BRAF
V600E
 or RET/PTC1 
expressing thyroid cells. Apigenin+Akti1/2 also increased RAIU in thyroid tumor cells from 
TRβPV/PV mice. Accordingly, Apigenin+Akti1/2 may increase TSH-stimulated RAIU in various 
thyroid tumors that carry the BRAF
V600E
 mutation, RET/PTC1 rearrangement, or PI3K 
overactivation. A recent study reported a synergistic effect between Apigenin and an Akt 
inhibitor on cytotoxic effects of PLX4032-treated anaplastic thyroid carcinoma cells (45). It 
would also be of interest to further examine whether other flavonoids with a similar structure as 
Apigenin would have the same effect. 
 
In summary, our studies suggest that Apigenin as a dietary supplement that, along with Akt 
inhibitors, can further enhance the efficacy of radioiodine therapy for thyroid cancer patients. 
Several Akt inhibitors, such as MK-2206 or GSK2110183, are currently in oncological pipelines 
to treat other types of cancer. Our finding has potential for translation into clinical trials upon 
confirmation in preclinical thyroid cancer mouse models.  
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Figure 1. TSH-stimulated RAIU in PCCl3 cells can be further increased by various 
reagents. Cells were withdrawn from TSH (-TSH) for 5 days and then stimulated with TSH 
(+TSH) for 24 hrs followed by treatment with 10 µl DMSO (vehicle control), 10 µM Akti1/2, 10 
µM LY294002, 3 µM 17-AAG or 40 µM PD98059 for 24 hrs before RAIU analysis. RAIU in 
+TSH/DMSO treated cells was significantly higher than in –TSH/DMSO-treated cells.  RAIU in 
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TSH-stimulated cells treated with Akti1/2, LY294002, 17-AAG and PD98059 was significantly 
higher than in DMSO-treated cells. Data are expressed as mean + SD (n=3). 
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Figure 2.  Apigenin further increases RAIU activity in Akti1/2-treated PCCl3 rat thyroid 
cells.  (A) RAIU in Apigenin (AP)-treated cells was not significantly higher than in DMSO-
treated cells, yet RAIU in AP+Akti1/2-treated cells was significantly higher than in Akti1/2-
treated cells. RAIU in Akti1/2-treated cells was significantly higher than in DMSO-treated cells. 
(B) RAIU in cells treated with a combination of 20 µM AP and 10 µM or 30 µM Akti1/2 is 
significantly higher than RAIU in cells treated with 10 µM or 30 µM Akti1/2 alone. At 50 µM, 
AP did not significantly further increase RAIU compared to 20 µM AP in the presence or 
absence of Akti1/2 treatment. RAIU in cells treated with Akti1/2 at 10 µM and 30 µM were 
significantly higher than in DMSO-treated control. (C) Western blots show that phospho-Akt 
levels are decreased in cells treated with AP, Akti1/2, or AP+Akti1/2. Total Akt levels remained 
the same (data not shown). β-actin served as a loading control. For panels (A) and (B), data are 
expressed as mean + SD (n=3). All cells were acutely stimulated with TSH for 24 hr prior to 
treatments. 
 
  
 Page 29 of 39 
Th
yr
oi
d
A
pi
ge
ni
n 
in
 C
om
bi
na
tio
n 
w
ith
 A
kt
 In
hi
bi
tio
n 
Si
gn
ifi
ca
nt
ly
 E
nh
an
ce
s T
hy
ro
tro
pi
n-
sti
m
ul
at
ed
 R
ad
io
io
di
de
 A
cc
um
ul
at
io
n 
in
 T
hy
ro
id
 C
el
ls 
(do
i: 1
0.1
08
9/t
hy
.20
13
.06
14
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
30 
30 
 
 
 
Figure 3.  Akt inhibition appears to be permissive for Apigenin to enhance RAIU in PCCl3 
cells. (A) RAIU is significantly increased by AP treatment in shAkt1/2 stably-transfected cells 
but not in vector-transfected cells. RAIU in shAkt1/2-stably transfected cells is significantly 
higher than RAIU in vector-transfected cells. (B) Western blots show that phospho-Akt levels 
are decreased in shAkt1/2 stably-transfected cells due to effective knockdown of total Akt (data 
not shown). Note an increase in Mr of NIS in shAkt1/2 transfected cells treated with AP. (C) 
RAIU in AP-treated cells is greater than in DMSO-treated cells under 4H+TSH conditions but 
not under 4H or 6H conditions. Cells were deprived of TSH and insulin (4H) with 0.2% serum 
for 5 days, and then 4H culture media was replaced with 4H+TSH or 6H (4H+TSH+insulin) 
culture media for 24 hrs before adding either DMSO vehicle or AP for an additional 24 hrs. (D) 
Western blots show that phospho-Akt level in cells with 4H+TSH is lower than that in cells 
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treated with 4H or 6H media, and AP suppressed phospho-Akt levels. NIS is undetectable in 
cells under 4H media but was evidently increased in cells under 4H+TSH and 6H. Total Akt 
levels remained the same in all lanes (data not shown). For panels (A) and (C), data are 
expressed as mean + SD (n=3). In panels (B) and (D), GAPDH served as a loading control. 
Hyperglycosylated NIS is indicated with ( ) and hypoglycosylated NIS with ( ). 
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Figure 4. Apigenin increases iodide influx rate in Akti1/2-treated PCCl3 cells. (A) Western 
blots show that total or cell surface NIS protein levels are not changed by AP in Akti1/2-treated 
cells. Exposure times for total and cell surface NIS were 2 and 10 minutes respectively. 
Hyperglycosylated NIS is indicated with ( ) and hypoglycosylated NIS with ( ). Na
+
/K
+
 
ATPase served as a loading control for cell surface proteins and β-actin for total cell lysates. 
Enrichment of cell surface proteins was confirmed by the absence of β-actin. (B) Efflux assays 
show that neither Akti1/2 nor AP+Akti1/2 treatment significantly decrease the iodide efflux rate 
compared to DMSO treatment. 17-AAG, known to significantly decrease the iodide efflux rate, 
was used as the positive control. The iodide efflux rate is shown as the percentage of iodide 
remaining in the cells plotted at 2 min intervals. (C) Iodide kinetics assay show that the 
maximum velocity of iodide influx (Vmax) was increased by AP+Akti1/2 compared to Akti1/2 
alone, yet there is little change in the Km value. Vmax and Km from two independent 
experiments are expressed as average + range. All cells were acutely stimulated with TSH for 24 
hr prior to treatments. 
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Figure 5. Apigenin’s effect to further increase RAIU in Akti1/2-treated PCCl3 cells 
requires p38 MAPK activity. (A) In the presence of SB203580, RAIU in cells treated with 
DMSO, AP, Akti1/2 and AP+Akti1/2 is significantly decreased and AP does not significantly 
increase RAIU in Akti1/2-treated cells. (B) Western blots show an increase in the relative 
abundance of non-phosphorylated MAPKAPK2, an immediate downstream effector of p38 
MAPK, thereby confirming the inhibition of p38 MAPK by SB203580. The NIS protein level is 
not decreased by SB203580. Note an increase in Mr of NIS in cells treated with AP+Akti1/2 in 
the presence or absence of SB203580. (C, D) Similar results were obtained using an allosteric 
p38 MAPK inhibitor, BIRB-796. In panels (A) and (C), data are expressed as mean + SD (n=3). 
In panels (B) and (D), GAPDH served as a loading control. Arrows  and <-- indicate 
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phosphorylated and non-phosphorylated MAPKAPK2, respectively. Hyperglycosylated NIS is 
indicated with ( ) and hypoglycosylated NIS with ( ). All cells were acutely stimulated with 
TSH for 24 hr prior to treatments. 
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Figure 6. Apigenin’s effect to further increase RAIU in Akti1/2-treated PCCl3 cells is 
independent of PKC-δ. Cells were transfected with 10 nM of scrambled (Scr) or PKC-δ siRNA 
for 24 hrs followed by treatment with reagents for additional 24 hrs. (A) RAIU in Scr siRNA-
transfected cells was not significantly different from PKC-δ siRNA-transfected cells. Data are 
expressed as mean + SD (n=3). (B) PKC-δ knockdown was confirmed by evident decrease in 
PKC-δ protein level in Western blots. NIS protein level was moderately decreased by PKC-δ 
knockdown. Hyperglycosylated NIS is indicated with ( ) and hypoglycosylated NIS with ( ). 
GAPDH served as a loading control.   
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Figure 7. Apigenin in combination with Akti1/2 increases RAIU in BRAF expressing 
PCCl3 cells and in thyroid tumor cells from TRβPV/PV mice. (A) RAIU in doxycycline-
induced cells is significantly decreased compared to uninduced cells. RAIU in AP+Akti1/2-
treated cells is significantly higher than Akti1/2-treated cells in both uninduced and induced 
cells. (B) Western blots show that total NIS protein levels are decreased nearly by half in 
BRAF
V600E
 expressing cells. Hyperglycosylated NIS is indicated with ( ) and hypoglycosylated 
NIS with ( ). Note an increase in Mr of NIS by AP+Akti1/2 in both uninduced and induced 
cells. GAPDH served as a loading control.  (C) Primary cultured thyroid tumor cells from 
TRβPV/PV mice were treated with DMSO or AP+Akti1/2, one day post-seeding. RAIU in 
AP+Akti1/2-treated cells was significantly greater than RAIU in DMSO treated cells. For (A) 
and (C), data are expressed as mean + SD (n=3). 
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